Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
The rising prevalence of diabetes and obesity, growing research and development activities, and increasing investments drive the market
N Engl J Med 398:205216
Novo Nordisk's patent for Saxenda expires later this year, and rivals Teva, Pfizer and Mylan are all expected to launch generic versions of liraglutide later in 2024
Moreover, xanthine dehydrogenase and glutathione synthase gene expression were downregulated, whereas glucose-6-phosphate dehydrogenase was upregulated compared to control
US$ 21.18
US$ 29.23
US$ 28.70
US$ 23.26
US$ 28.59
US$ 28.38
US$ 21.43
US$ 23.00
